Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00273312 | Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma | PHASE2 | COMPLETED | 25 | — | — | Jan 1, 2006 | - | Feb 7, 2017 | 7 | United States, Hong Kong +2 |
| Arm | Type | Description |
|---|---|---|
| Patupilone | EXPERIMENTAL | was administered at 10 mg/m2, as a single intravenous infusion over 20 minutes, once every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Patupilone | DRUG | Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials |
Inclusion criteria: \- Hepatocellular carcinoma patients with at least 1 previously un-irradiated, measurable lesion without any systemic single agent or combination chemotherapy. Previous local therapy is allowed. Exclusion criteria: Additional protocol-defined inclusion/exclusion criteria apply...